FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/04/065046 [Registered on: 02/04/2024] Trial Registered Prospectively
Last Modified On: 30/09/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda
Preventive 
Study Design  Single Arm Study 
Public Title of Study   Role of khadirastak kwatha and manjisthadi taila(external application) in treatment of psoriasis 
Scientific Title of Study   Clinical Evaluation of Khadirastaka Kvatha and Local Application of Manjisthadi Taila in the Management of Psoriasis  
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Feni R Patel 
Designation  PG Scholar 
Affiliation  J.S.Ayurved Mahavidyalay 
Address  Department of Kayachikitsa J S Ayurved Mahavidyalaya and P D Patel Ayurved Hospital college road kheda nadiad

Kheda
GUJARAT
387001
India 
Phone  8758189589  
Fax    
Email  fenipatel676@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Prof Dr Manish Patel  
Designation  Professor and HOD 
Affiliation  J.S.Ayurved Mahavidyalay 
Address  Department of Kayachikitsa J S Ayurved Mahavidyalaya and P D Patel Ayurved Hospital college road kheda nadiad

Kheda
GUJARAT
387001
India 
Phone  9979589865  
Fax    
Email  manishayu97@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Prof Dr Manish Patel  
Designation  Professor and HOD 
Affiliation  J.S.Ayurved Mahavidyalay 
Address  Department of Kayachikitsa J S Ayurved Mahavidyalaya and P D Patel Ayurved Hospital college road kheda nadiad

Kheda
GUJARAT
387001
India 
Phone  9979589865  
Fax    
Email  manishayu97@yahoo.com  
 
Source of Monetary or Material Support  
sundar ayurved pharmacy, J S ayurved mahavidyalay and P D patel ayurved hospital,college road,Nadiad-387001 
 
Primary Sponsor  
Name  J S Ayurved Mahavidhyalay 
Address  J S Ayurved Mahavidyalay, college road, nadiad 387001 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
J S Ayurved Mahavidhyalay  J S Ayurved Mahavidyalay, college road, nadiad,387001 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Feni R Patel  J S Ayurved mahavidyalay  Department of kayachikitsa J S Ayurved Mahavidyalay P D Patel ayurved Hospital
Kheda
GUJARAT 
8758189589

fenipatel676@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC for human research   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:L409||Psoriasis, unspecified. Ayurveda Condition: KUSHTHAM,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: khadirastak kwatha, Reference: yogaratnakar kustha chikitsaa 63, Route: Oral, Dosage Form: Kwatha/ Kashaya, Dose: 40(ml), Frequency: bd, Bhaishajya Kal: Abhakta, Duration: 8 Weeks, anupAna/sahapAna: Yes(details: -warm water), Additional Information: -
(2) Medicine Name: manjisthadi taila, Reference: yogaratnakar kustha chikitsa 142, Route: Topical, Dosage Form: Taila, Dose: 5(ml), Frequency: bd, Bhaishajya Kal: Muhurmuhu, Duration: 8 Weeks, anupAna/sahapAna: No, Additional Information: -
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  patients will be diagnosed with psoriasis with the help of presence of signs and symptoms like scaling(dalana),itching(kandu),erythema (krusna aruna varna),loss of perspiration (asvedanam),dryness(rukshta),auspitz sign,candle grease sign,koebners phenomenon 
 
ExclusionCriteria 
Details  1.Pregnant or lactating females.
2.Patients who have taken medicine of corticosteroid drugs or immune-suppressants or other biological medicines within last 6 months.
3.Known case of diseases like AIDS, STD, TB, heart diseases and other disorders which lead to fetal condition for the patients.
4.Patients having diabetes mellitus.
5.Other concomitant skin disease occurring with allergic reaction of any other disease.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
To observe and find out changes in signs and symptoms of the psoriasis after the oral administration of khadirastaka kwatha and local application of manjisthadi taila.  2 weeks 
 
Secondary Outcome  
Outcome  TimePoints 
1.To evaluate the changes in PASI index in the patients of psoriasis.
2.To find out the improvement in quality of life through changes in DLQI in the patients of psoriasis.
 
8 weeks 
 
Target Sample Size   Total Sample Size="20"
Sample Size from India="20" 
Final Enrollment numbers achieved (Total)= "20"
Final Enrollment numbers achieved (India)="20" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   10/04/2024 
Date of Study Completion (India) 24/06/2025 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details
Modification(s)  
This will be submitted in form of dissertation 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  
Psoriasis is a complex, chronic, multifactorial, inflammatory disease that involves hyper proliferation of keratinocytes in the epidermis, with an increase in the epidermal cell turnover rate. 20 patients  of psoriasis who fulfill the inclusion criteria were  selected from OPD and gave them oral administration of khadirastak kwatha 40 ml twice a day and manjisthadi taila for local application twice a day. Patients were treated for 8 weeks and assessed before and after the treatment. It shows significant effect in all symptoms as well as PASI and DLQI.  
Close